Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.

ABSTRACT:

Background and objectives

The standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT), novel antihormonal therapies (NHT) and/or chemotherapy. Patients with newly diagnosed oligometastatic prostate cancer (omPCa) represent a distinct subgroup of mHSPC, for which the optimal treatment, particularly the role of radical prostatectomy (RP) and metastasis-directed therapy (MDT), is currently under debate.

Materials and methods

In this single center, retrospective analysis, 43 patients with newly diagnosed omPCa were included. All patients underwent RP as part of a multimodal, personalized treatment approach. Other treatments included ADT, NHT, MDT (surgery or radiotherapy), adjuvant radiotherapy (prostati

SUBMITTER: Schutz V 

PROVIDER: S-EPMC11666478 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature